Advances in Therapy

, Volume 24, Issue 5, pp 1085–1097 | Cite as

Effectiveness of mesalamine and propolis in experimental colitis

  • Ahmet Aslan
  • Muhyittin Temiz
  • Esin Atik
  • Gurbuz Polat
  • Nuray Sahinler
  • Elmir Besirov
  • Nedim Aban
  • Cem Kaan Parsak


This study was conducted to investigate the effects of propolis and mesalamine on experimental colitis in rats. Distal colitis was induced in rats by intracolonic instillation of 2 mL of 4% acetic acid. The animals were randomly assigned to 5 groups: group 1, control, (n=8); group 2, colitis, received no treatment (n=8); group 3, colitis+mesalamine, 2 mL once a day via an enema (n=8); group 4, colitis+propolis, 600 mg/kg once a day via intragastric lavage (n=8); and group 5, colitis+ mesalamine+propolis for 1 wk (n=8). Levels of nitric oxide were statistically significantly different in comparisons between groups 1 and 2, groups 2 and 3, and groups 4 and 5. Malondialdehyde levels were significantly different when group 2 was compared with groups 3, 4, and 5. A significant difference was observed when group 3 was compared with group 4 for myeloperoxidase. Most propolis-treated rats had normal histology; mesalamine-treated and propolis+mesalamine-treated rats had inflammatory cell infiltration at rates of 50% and 33%, respectively. The investigators concluded that propolis and mesalamine are efficient independently and in combination, but that their combined effect was not observed to be additive in experimental colitis.


mesalamine propolis experimental colitis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Podolsky DK. Inflammatory bowel disease.N Engl J Med. 2002;347:417–429.PubMedCrossRefGoogle Scholar
  2. 2.
    Reddy SN, Bazzocchi G, Chan S, et al. Colonic motility and transit in health and ulcerative colitis.Gastroenterology. 1991;5:1289–1297.Google Scholar
  3. 3.
    Al MoutaeryA. Proglumide attenuates experimental colitis in rats.Exp Toxicol Pathol. 2005;56: 327–332.PubMedCrossRefGoogle Scholar
  4. 4.
    Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues.Am J Gastroenterol. 2003;98:18–23.CrossRefGoogle Scholar
  5. 5.
    Ahnfelt-Ronne I, Nielsen OH. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger.Agents Actions. 1987;21:191–194.PubMedCrossRefGoogle Scholar
  6. 6.
    Aruoma OI, Wasil M, Halliwell B, Hoey BM, Butler J. The scavenging of oxidants by sulfasalazine and its metabolites: a possible contribution to their anti-inflammatory effects?Biochem Pharmacol. 1987;36:3739–3742.PubMedCrossRefGoogle Scholar
  7. 7.
    Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.J Clin Invest. 1982;69:494–497.PubMedCrossRefGoogle Scholar
  8. 8.
    Nielsen OH, Verspaget HW, Elmgreen J. Inhibition of intestinal chemotaxis to leukotriene B4 by sulfasalazine, olsalazine, and 5-aminosalicylic acid.Aliment Pharmacol Ther. 1988;2:203–211.PubMedGoogle Scholar
  9. 9.
    Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.Gut. 1992;33:929–932.PubMedCrossRefGoogle Scholar
  10. 10.
    Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference?Acta Drug Deliv Rev. 2005;57:281–302.CrossRefGoogle Scholar
  11. 11.
    Burdock GA. Review of the biological properties and toxicity of bee propolis (propolis).Food Chem Toxicol. 1998;36:347–363.PubMedCrossRefGoogle Scholar
  12. 12.
    Castaldo S, Capasso F. Propolis, an old remedy used in modern medicine.Fitoterapia. 2002;73:1–6.CrossRefGoogle Scholar
  13. 13.
    Nagai T, Inoue R, Inoue H, Suzuki N. Preparation and antioxidant properties of water extract of propolis.Food Chemistry. 2003;80:29–33.CrossRefGoogle Scholar
  14. 14.
    Borrelli F, Maffia P, Pinto L, et al. Phytochemical compounds involved in antiinflammatory effects.Fitoterapia. 2002;73:53–63.CrossRefGoogle Scholar
  15. 15.
    Kujumgiev A, Tsvetkova I, Serkedjieva Y, Bankova V, Christov R, Popov S. Antibacterial, antifungal and antiviral activity of propolis of different geographic origin.J Ethnopharmacol. 1999;64:235–240.PubMedCrossRefGoogle Scholar
  16. 16.
    Kartal M, Yildiz S, Kaya S, Kurucu S, Topcu G. Antimicrobial activity of propolis samples from two different regions of Anatolia.J Ethnopharmacol. 2003;86:69–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Russo A, Cardile V, Sanchez F, Troncoso N, Vanella A, Garbarino JA. Chilean propolis: antioxidant activity and antiproliferative action in human tumor cell lines.Life Sci. 2004;76:545–558.PubMedCrossRefGoogle Scholar
  18. 18.
    Kolankaya D, Selmanoglu G, Sorkun K, Salih B. Protective effects of Turkish propolis on alcohol-induced serum lipid changes and liver injury in male rats.Food Chemistry. 2002;78:213–217.CrossRefGoogle Scholar
  19. 19.
    Borrelli F, Izzo AA, Di Carlo G, et al. Effect of a propolis extract and caffeic acid phenethyl ester on formation of aberrant crypt foci and tumors in the rat colon.Fitoterapia. 2002;73:38–43.CrossRefGoogle Scholar
  20. 20.
    Banskota AH, Tezuka Y, Adnyana IK, et al. Hepatoprotective andanti-Helicobacter pylori activities of constituents from Brazilian propolis.Phytomedicine. 2001;8:16–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Lu LC, Chen YW, Chou CC. Antibacterial activity of propolis againstStaphylococcus aureus.Int J Food Microbiol. 2005;102:213–220.PubMedCrossRefGoogle Scholar
  22. 22.
    Uzel A, Sorkun K, Oncag O, Cogulu D, Gencay O, Salih B. Chemical compositions and antimicrobial activities of four different Anatolian propolis samples.Microbiol Res. 2005;160:189–195.PubMedCrossRefGoogle Scholar
  23. 23.
    Popova M, Silici S, Kaftanoglu O, Bankova V. Antibacterial activity of Turkish propolis and its qualitative and quantitative chemical composition.Phytomedicine. 2005;12:221–228.PubMedCrossRefGoogle Scholar
  24. 24.
    Popov SV, Markov PA, Nikitina IR, Petrishev S, Smirnov V, Ovodov YS. Preventive effect of a pectic polysaccharide of the common cranberryVaccinium oxycoccos L. on acetic acid-induced colitis in mice.World J Gastroenterol. 2006;12:6646–6651.PubMedGoogle Scholar
  25. 25.
    Krell R.Value-Added Products From Beekeeping. FAO Agricultural Services Bulletin No. 124. Rome, Italy: Food and Agriculture Organization of the United Nations; 1996.Google Scholar
  26. 26.
    Aksoyek S, Cinel I, Avian D, et al. Intestinal ischemic preconditioning protects the intestine and reduces bacterial translocation.Shock. 2002;18:476–480.PubMedCrossRefGoogle Scholar
  27. 27.
    Yagi K. Simple procedure for specific enzyme of lipid hydroperoxides in serum or plasma.Methods Mol Biol. 1998;108:107–110.PubMedGoogle Scholar
  28. 28.
    Aebi H. Catalase. In: Bergmayer HV, ed.Methods of Enzymatic Analysis. London: Academic Press Inc.; 1974:673–677.Google Scholar
  29. 29.
    Grisham MB, Hernandez LA, Granger DN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia.Am J Physiol. 1987;251:649–653.Google Scholar
  30. 30.
    Glowick SP, Kaplan SP.Methods in Enzymology. New York, NY: Academic Press; 1955:769–782.Google Scholar
  31. 31.
    Pravda J. Radical induction theory of ulcerative colitis.World J Gastroenterol. 2005;11:2371–2384.PubMedGoogle Scholar
  32. 32.
    Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease.Clin Microbiol Rev. 2002;15:79–94.PubMedCrossRefGoogle Scholar
  33. 33.
    Pavlick KP, Laroux FS, Fuseler J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease.Free Radie Biol Med. 2002;33:311–322.CrossRefGoogle Scholar
  34. 34.
    Southey A, Tanaka S, Murakami T, et al. Pathophysiological role of nitric oxide in rat experimental colitis.Int J Immunopharmacol. 1997;19:669–676.PubMedCrossRefGoogle Scholar
  35. 35.
    Song YS, Park EH, Hur GM, Ryu YS, Kim YM, Jin C. Ethanol extract of propolis inhibits nitric oxide synthase gene expression and enzyme activity.J Ethnopharmacol. 2002;80:155–161.PubMedCrossRefGoogle Scholar
  36. 36.
    Wallace JL. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease.Dig Liver Dis. 2003;35:35–40.CrossRefGoogle Scholar
  37. 37.
    Tuzun A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease.Clin Biochem. 2002:35:569–572.PubMedCrossRefGoogle Scholar
  38. 38.
    Kruidenier L, Kuiper I, Van Duijn W, et al. unbalanced secondary mucosal antioxidant response in inflammatory bowel disease.J Pathol. 2003;201:17–27.PubMedCrossRefGoogle Scholar

Copyright information

© Health Communications Inc 2007

Authors and Affiliations

  • Ahmet Aslan
    • 1
  • Muhyittin Temiz
    • 1
  • Esin Atik
    • 2
  • Gurbuz Polat
    • 3
  • Nuray Sahinler
    • 4
  • Elmir Besirov
    • 5
  • Nedim Aban
    • 5
  • Cem Kaan Parsak
    • 6
  1. 1.Department of General SurgeryMustafa Kemal UniversityAntakya-HatayTurkey
  2. 2.Department of Pathology, Faculty of MedicineMustafa Kemal UniversityAntakya-HatayTurkey
  3. 3.Department of Biochemistry, Faculty of MedicineMersin UniversityMersinTurkey
  4. 4.Faculty of AgricultureMustafa Kemal UniversityAntakya-HatayTurkey
  5. 5.Department of General Surgery, Faculty of MedicineMustafa Kemal UniversityAntakya-HatayTurkey
  6. 6.Department of General SurgeryCukurova University Medical FacultyBalcali, AdanaTurkey

Personalised recommendations